• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    BioXcel Therapeutics, Inc. - Common Stock (NQ:BTAI)

    0.8034 -0.0416 (-4.92%)
    Streaming Delayed Price Updated: 2:55 PM EDT, Jul 29, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about BioXcel Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 Next >
    News headline image
    Levi & Korsinsky, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of BioXcel Therapeutics, Inc.
    From Levi & Korsinsky, LLP
    Via GlobeNewswire
    News headline image
    Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
    From Halper Sadeh LLC
    Via Business Wire
    News headline image
    Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
    From Halper Sadeh LLC
    Via Business Wire
    News headline image
    Synergy Corp. (NASDAQ: SNYR) 1,600+ Nationwide Store Rollout – PPCB, SNGX, BTAI, HIT + Other Disruptive Stocks Moving Now!
    Via AB Newswire
    Topics Artificial Intelligence
    News headline image
    Avant Technologies and Ainnova Tech Announce Enhanced Patient Recruitment Strategy Ahead of FDA Clinical Trial
    EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:RLYB),(NASDAQ:BTAI),(NYSE:PFE) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Topics Artificial Intelligence
    News headline image
    Synergy Inc. (NASDAQ: SNYR) CEO on Air Spotlights on FOCUSfactor® Legacy, Energy Beverage & Weight Loss – Poised for Explosive Growth – More Stocks Inside
    Via AB Newswire
    News headline image
    Real-World Deployments Signal AI Healthcare Is Ready for Scale
    EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NASDAQ:BTAI),(OTCPK:HWAIF),(OTCQX:WHTCF) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Topics Artificial Intelligence
    News headline image
    The Next Wave of Health AI: Analysts Highlight Breakthroughs in Clinical Trials and Patient Care
    USA News Group Commentary Issued on behalf of Avant Technologies Inc. Vancouver, BC – December 17, 2024 – USA News Group News Commentary – Artificial intelligence (AI) is on the brink of becoming a... 
    Via FinancialNewsMedia
    Topics Artificial Intelligence
    Leading The Charge: Tonix Pharmaceuticals And The Future Of CNS Therapeutics
    Via Get News
    News headline image
    BIOXCEL ALERT: Bragar Eagel & Squire, P.C. is Investigating BioXcel Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
    EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END 
    Via FinancialNewsMedia
    BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Long Term Investor Notice: Investigation of Potential Wrongdoing ↗
    San Diego, CA -- (SBWIRE) -- 12/08/2023 -- An investigation on behalf of current long-term investors in shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) concerning potential breaches of fiduciary... 
    Via SBWire
    News headline image
    Unlocking AI investment opportunities in healthcare
    AI is revolutionizing healthcare by improving diagnosis and accelerating drug discovery. An often-overlooked sector with a wealth of AI opportunities. 
    Via MarketBeat
    Topics Artificial Intelligence ETFs
    News headline image
    Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
    From FN Media Group LLC
    Via GlobeNewswire
    BioXcel Therapeutics Inc. (NASDAQ: BTAI) Leading the Way in Wednesday Trading Based on Percentage Gain
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    BIOXCEL ALERT: Bragar Eagel & Squire, P.C. is Investigating BioXcel Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire, P.C.
    Via Business Wire
    NASDAQ: BTAI Investor Alert: Deadline on September 5, 2023 in Lawsuit Against BioXcel Therapeutics, Inc. ↗
    San Diego, CA -- (SBWIRE) -- 09/05/2023 -- The Shareholders Foundation announced that a deadline is coming up on September 5, 2023 in the lawsuit filed for certain investors of BioXcel Therapeutics,... 
    Via SBWire
    Topics Lawsuit
    News headline image
    BTAI DEADLINE TOMORROW: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important September 5 Deadline in Securities Class Action – BTAI
    From The Rosen Law Firm, P.A.
    Via Business Wire
    News headline image
    BTAI DEADLINE ALERT: ROSEN, A LONGSTANDING LAW FIRM, Encourages BioXcel Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important September 5 Deadline in Securities Class Action - BTAI
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Lawsuit
    News headline image
    BIOXCEL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioXcel Therapeutics, Inc. and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire, P.C.
    Via Business Wire
    News headline image
    BIOXCEL 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioXcel Therapeutics, Inc. - BTAI
    From Kahn Swick & Foti, LLC
    Via Business Wire
    News headline image
    The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioXcel Therapeutics, Inc. (BTAI)
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    News headline image
    4-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
    Via ACCESSWIRE
    News headline image
    BIOXCEL THERAPEUTICS, INC. (NASDAQ: BTAI) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioXcel Therapeutics, Inc.
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important September 5 Deadline in Securities Class Action - BTAI
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Lawsuit
    News headline image
    Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioXcel, Seagate, and Baxter and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    ROSEN, A RESPECTED AND LEADING FIRM, Encourages BioXcel Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important September 5 Deadline in Securities Class Action - BTAI
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Lawsuit
    News headline image
    ROSEN, A LEADING AND TOP RANKED LAW FIRM, Encourages BioXcel Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important September 5 Deadline in Securities Class Action – BTAI
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    BioXcel Therapeutics, Inc. Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds BTAI Investors of Securities Fraud Class Action Lawsuit Filed On Their Behalf
    From Kessler Topaz Meltzer & Check, LLP
    Via Business Wire
    News headline image
    ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BTAI
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Lawsuit
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.